Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560721 | 1.00 | FPR2 (0.57) | FPR2ALDH1A1LMNACTSKFOLH1 | |
| SCHEMBL3451593 | 0.85 | PSMB5 (0.57) | ALDH1A1LMNACTSKPSMB5ACE | |
| SCHEMBL17833228 | 0.85 | PSMB5 (0.57) | ALDH1A1LMNACTSKPSMB5ACE | |
| SCHEMBL3451636 | 0.85 | PSMB5 (0.57) | ALDH1A1LMNACTSKPSMB5ACE | |
| SCHEMBL8255500 | 0.84 | ALDH1A1 (0.51) | ALDH1A1LMNACTSKFOLH1PSMB5 | |
| SCHEMBL27723661 | 0.84 | ITGB1 (0.55) | ALDH1A1LMNACTSKFOLH1PSMB5 | |
| SCHEMBL5172068 | 0.84 | MME (0.56) | ALDH1A1LMNACTSKPSMB5ACE | |
| SCHEMBL27723663 | 0.84 | ITGB1 (0.55) | ALDH1A1LMNACTSKFOLH1PSMB5 | |
| SCHEMBL4703394 | 0.84 | CTSK (0.69) | FPR2ALDH1A1LMNACTSKFOLH1 | |
| SCHEMBL5869760 | 0.84 | ALDH1A1 (0.51) | ALDH1A1LMNACTSKFOLH1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LD. (GB) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | IKBKE, IKBKB, NFKBIA | FPR2 3850/4885ALDH1A1 2776/4885LMNA 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.